Hmm, is your consultant possibly putting you in a study??? The below is interesting and indicates that they might be wanting to do a larger study....
Intralymphatic treatment with GAD-alum in LADA is without clinical or other safety concerns over a 12-month period. As in a similar protocol used in type 1 diabetes, treatment exerts a strong immunological impact and is compatible with protection of beta-cell function preferentially in...
Hopefully that should clarify things for you (and those of us on the forum, should you choose to share). Good luck.